PAS
CHRS icon

Point72 Asia (Singapore)’s Coherus Oncology CHRS Stock Holding History

Point72 Asia (Singapore)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,408
Closed -$8.14K – 1101
2024
Q1 		$8.14K Sell
3,408
-15,914
-82% -$39.2K ﹤0.01% 1010
2023
Q4 		$64.3K Buy
+19,322
New +$51.8K 0.02% 276

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asia (Singapore)'s CHRS Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Coherus Oncology (CHRS) in Q2 2024, closing a stake of 3,408 shares — an estimated $8.14K sold.

Point72 Asia (Singapore) first reported a position in CHRS in Q4 2023 and held it in 2 quarters. The position peaked at $64.3K in Q4 2023. 135 funds tracked by Wall St. Rank hold CHRS as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Coherus Oncology position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 3,408 Coherus Oncology shares in Q2 2024, an estimated $8.14K.
  • Point72 Asia (Singapore) first reported a position in Coherus Oncology in Q4 2023 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Coherus Oncology position peaked at $64.3K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.